Name: Return on Assets (ROA)

Definition: ROA shows how efficiently the company turns everything it owns — its entire asset base — into net profit after all costs and taxes. A higher ROA means the business squeezes more profit from its assets. Lower ROA might reflect poor asset utilization or heavy reliance on expensive financing.

Interpretation:
• In '2021', SCNX's return on assets was -92.2%, representing returns generated from total assets. Industry average for Other Pharmaceuticals in '2021' stood at -13.4%.
• In '2022', SCNX's return on assets was -73.3%, representing returns generated from total assets. The increase since '2021' reflects strengthening financial performance. Industry average for Other Pharmaceuticals in '2022' stood at -13.9%. Industry average declined by 0.5% from previous year.
• In '2023', SCNX's return on assets was -219.7%, representing returns generated from total assets. The decline from '2022' may indicate some operational or financial challenges. Industry average for Other Pharmaceuticals in '2023' stood at -15.2%. Industry average declined by 1.3% from previous year.
• In '2024', SCNX's return on assets was 15.4%, representing returns generated from total assets. The increase since '2023' reflects strengthening financial performance. Industry average for Other Pharmaceuticals in '2024' stood at -0.6%. Industry average increased by 14.6% compared to previous year.
Overall, SCNX's return on assets has been volatile but showed an upward trend over the past 4 years.

Formula: ROA = Net Income / Total Assets

Good Range: Commonly 5%-15%.